Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer.
Journal Of Clinical Oncology : Official Journal Of The American Society Of Clinical Oncology
Bardia, Aditya A; Kaklamani, Virginia V; Wilks, Sharon S; Weise, Amy A; Richards, Donald D; Harb, Wael W; Osborne, Cynthia C; Wesolowski, Robert R; Karuturi, Meghan M; Conkling, Paul P; Bagley, Rebecca G RG; Wang, Yamei Y; Conlan, Maureen G MG; Kabos, Peter P
Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer.
Annals Of Oncology : Official Journal Of The European Society For Medical Oncology
Chung, J H JH; Pavlick, D D; Hartmaier, R R; Schrock, A B AB; Young, L L; Forcier, B B; Ye, P P; Levin, M K MK; Goldberg, M M; Burris, H H; Gay, L M LM; Hoffman, A D AD; Stephens, P J PJ; Frampton, G M GM; Lipson, D M DM; Nguyen, D M DM; Ganesan, S S; Park, B H BH; Vahdat, L T LT; Leyland-Jones, B B; Mughal, T I TI; Pusztai, L L; O'Shaughnessy, J J; Miller, V A VA; Ross, J S JS; Ali, S M SM